+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

2024 Physician Office Diagnostics Forecasts for 300 Tests: 2023 Supplier Shares and Strategies, Instrumentation Review, Emerging Technologies, Opportunities for Suppliers

  • PDF Icon

    Report

  • 970 Pages
  • July 2024
  • Region: Global
  • VPG Market Research
  • ID: 4856612
This new report provides a comprehensive analysis of the POC infectious disease testing market, including trends, dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. This report will help diagnostic product suppliers develop effective business, R&D and marketing strategies for the global POC infectious disease testing market.

Rationale

The growing economic pressures on hospitals, coupled with advances in diagnostic technologies, intensifying competition among suppliers and physicians, and changing consumer demands are shifting diagnostic testing from hospitals and commercial laboratories closer to the patient.

Market Segmentation Analysis

  • Review of five POC market segments, including their dynamics, trends, structure, size, growth and major suppliers.
  • Five-year test volume and reagent sales forecasts for major infectious disease tests by market segment:
  • Physician Offices/Group Practices
  • Emergency Rooms
  • Ambulatory Care Centers
  • Surgery Centers
  • Birth Centers

Sales and Market Share Analysis

- Market shares of major infectious disease diagnostic reagent and instrument suppliers.

Current and Emerging Products

- Analysis of infectious disease diagnostic tests performed in POC testing locations.
  • Review of leading infectious disease testing analyzers, both currently marketed and those in development, including their operating characteristics, features and selling prices.

Technology Review

  • Emerging technologies and their applications for POC testing.
  • Comprehensive listings of companies developing or marketing coagulation testing technologies and products, by assay.

Competitive Assessments

  • Assessments of major suppliers and emerging market entrants including their sales, product portfolios, marketing tactics, joint ventures,
and new products in R&D.

Strategic Recommendations

  • Specific opportunities for new infectious disease testing instruments and reagent systems with potentiallysignificant market appeal during the next five years.
  • Design criteria for POC testing products.
  • Alternative business expansion strategies.
  • Potential market entry barriers and risks.

Methodology

This report is based on a combination of primary and secondary sources of information, including review of the latest technical and business publications, manufacturer product literature, industry analyst reports, and the publisher's proprietary data files.

Companies Mentioned

  • Abbott
  • Accriva
  • Agilent Technologies
  • Axis-Shield
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Bio/Data
  • bioMerieux
  • Bio-Rad
  • Cepheid
  • Chrono-Log
  • Corgenix
  • Decode Genetics
  • Diagnostica Stago
  • Diamedix
  • DiaSorin
  • Eiken Chemical
  • EKF Diagnostics
  • Fujirebio
  • Grifols
  • Helena Laboratories
  • Hologic
  • Horiba
  • Instrumentation Laboratory/Werfen
  • Kyowa Medex
  • Leica Biosystems
  • Lonza
  • Nihon Kohden
  • Ortho-Clinical Diagnostics
  • Polymedco
  • Qiagen
  • Roche
  • SDIX
  • Sekisui Diagnostics
  • Sequenom
  • Siemens Healthineers
  • Sienco
  • Sysmex
  • Takara Bio
  • Thermo Fisher
  • Tosoh
  • Wako